ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Bookmark and Share
Published: 9 Oct 2016
Views: 3108
Rating:
Save
Dr Giorgio Scagliotti - University of Turin, Turin, Italy

Dr Scagliotti speaks to ecancertv at ESMO 2016 about results from the confirmatory phase III trial ASCEND-5.

He summarises these results, confirming the benefit of ceritinib for lung cancer patients with ALK rearrangements who had previously received crizotinib, and goes on to consider the impact of kinase inhibitor therapy.

Video of the press conference in which these results were announced is available here.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.